Patents by Inventor Guy Mullenbach
Guy Mullenbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6642029Abstract: Methods and compositions are provided for efficient production of human insulin-like growth factor. Synthetic IGF I and IGF II genes are joined to leader and processing signals which provide for expression and secretion of the gene product in yeast. Enhanced yields of the product may then be recovered from the nutrient medium. Yeast strains S. cerevisiae AB103 (pYIGF-I-10/1) and AB103 (pYIGF-II-10/1) were deposited at the American Type Culture Collection on Apr. 23, 1983 and granted Accession Nos. 20673 and 20674, respectively.Type: GrantFiled: May 17, 1995Date of Patent: November 4, 2003Assignee: Chiron CorporationInventors: Pablo D. T. Valenzuela, Guy Mullenbach
-
Patent number: 6448379Abstract: Inhibitors, including antibodies, of IL8 binding to its receptors, that interact with the amino-terminal extracellular domain of the IL8 receptor and which compete with IL8 for receptor-binding, are disclosed. The inhibitors are useful modulators of IL8 receptor-mediated biological activity.Type: GrantFiled: September 14, 1993Date of Patent: September 10, 2002Assignee: Chiron CorporationInventors: Patricia Tekamp-Olson, Guy Mullenbach, Mary Ellen Wernette-Hammond
-
Patent number: 6436390Abstract: Inhibitors, including antibodies, of IL8 binding to its receptors, that interact with the amino-terminal extracellular domain of the IL8 receptor and which compete with IL8 for receptor-binding, are disclosed. The inhibitors are useful modulators of IL8 receptor-mediated biological activity.Type: GrantFiled: June 7, 1995Date of Patent: August 20, 2002Inventors: Patricia Tekamp-Olson, Guy Mullenbach, Mary Ellen Wernette-Hammond
-
Patent number: 6030799Abstract: Methods and compositions are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of Chlamydia trachomatis. A DNA construct including a replication system recognized by E. coli, and an MOMP gene under the transcriptional control of a .beta.-glactosidase promoter and terminator is provided. Recombinant phage .lambda.gtll/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.Type: GrantFiled: June 6, 1995Date of Patent: February 29, 2000Assignee: Washington Research FoundationInventors: Nina Agabian, Richard Stephens, Cho-Chou Kuo, Guy Mullenbach
-
Patent number: 5976530Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.Type: GrantFiled: February 13, 1997Date of Patent: November 2, 1999Assignees: Chiron Corporation, Hoechst Marion Roussel Deutschland GmbHInventors: Nancy L. Haigwood, Guy Mullenbach, Ernst-Guenter Afting, Eric Paul Paques
-
Patent number: 5821055Abstract: Methods and compositions are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of Chlamydia trachomatis. A DNA construct including a replication system recognized by E. coli, and an MOMP gene under the transcriptional control of a .beta.-galactosidase promoter and terminator is provided.Recombinant phage .lambda.gt11/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.Type: GrantFiled: June 6, 1995Date of Patent: October 13, 1998Assignees: Washington Research Foundation, Chiron CorporationInventors: Nina Agabian, Richard Stephens, Cho-Chou Kuo, Guy Mullenbach
-
Patent number: 5770714Abstract: Methods and compositions are provided for the production of a polypeptide which is immunologically cross-reactive with a naturally-occurring major outer membrane protein (MOMP) of Chlamydia trachomatis. A DNA construct including a replication system recognized by E. coli, and an MOMP gene under the transcriptional control of a .beta.-galactosidase promoter and terminator is provided. Recombinant phage .lambda.gt11/L2/33 was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, on Jan. 10, 1985 and granted accession no. 40157. L2 B9-F DNA was deposited at the American Type Culture Collection on Dec. 31, 1985, and granted accession No. 40217.Type: GrantFiled: June 6, 1995Date of Patent: June 23, 1998Assignees: Washington Research Foundation, Chiron CorporationInventors: Nina Agabian, Richard Stephens, Cho-Chou Kuo, Guy Mullenbach
-
Patent number: 5656269Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, reduced fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying the C-terminus by deletions.Type: GrantFiled: January 31, 1995Date of Patent: August 12, 1997Assignees: Chiron Corp., Behringwerke AGInventors: Nancy L. Haigwood, Guy Mullenbach, Ernst-Guenter Afting, Eric Paul Paques
-
Patent number: 5501853Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.Type: GrantFiled: December 22, 1986Date of Patent: March 26, 1996Assignees: Chiron Corporation, Behringwerke AGInventors: Nancy L. Haigwood, Ernest-Guenter Afting, Guy Mullenbach, Eric P. Paques
-
Patent number: 5439679Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.The plasmids designated 1, 2 and 3 were deposited at the A.T.C.C. on Dec. 20, 1985 and given A.T.C.C. designations 40214, 40215 and 40216, respectively.Type: GrantFiled: March 10, 1994Date of Patent: August 8, 1995Assignees: Chiron Corporation, Behringwerke AGInventors: Ernest-Guenter Afting, Eric-Paul Paques, Nancy L. Haigwood, Guy Mullenbach
-
Patent number: 5084390Abstract: Recombinant Cu/Zn superoxide dismutase (SOD) polymers having an extended in vivo half-life composed of SOD monomers covalently coupled to each other, carboxy terminus to amino terminus, by a polypeptide spacer such as a fragment of the hinge region of an immunoglobulin.Type: GrantFiled: February 14, 1990Date of Patent: January 28, 1992Assignee: Chiron CorporationInventors: Robert A. Hallewell, Guy Mullenbach